8-K 1 j0133_8k.htm 8-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 1, 2003

 

Bio-Technology General Corp.

(Exact name of issuer as specified in its charter)

 

Delaware

 

0-15313

 

13-3033811

(State or Other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

One Tower Center, 14th Floor
East Brunswick, New Jersey

 

08816

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (732) 418-9300

 

None.

(Former Name or Former Address, if Changed Since Last Report.)

 

 

 

ITEM 7.                                                     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

 

(c)                                  Exhibits.

 

99.1                         Press release issued by Bio-Technology General Corp. on May 1, 2003.

 

99.2                           Script of the presentation made by Dr. Sim Fass in a conference call discussing Bio-Technology General Corp.'s earnings results for the quarter ended March 31, 2003.

 

ITEM 9.                                                     REGULATION FD DISCLOSURE.

 

On May 1, 2003, Bio-Technology General Corp. announced its financial results for the three months ended March 31, 2003.  A copy of the Company’s press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.  The information contained in this report on Form 8-K is being furnished pursuant to “Item 12.  Results of Operations and Financial Condition” under Item 9 of Form 8-K, as directed by the U.S. Securities and Exchange Commission in Release No. 34-47583.

 

Filed herewith as Exhibit 99.2 is the script of the presentation made by Dr. Sim Fass in a conference call discussing Bio-Technology General Corp.'s earnings results for the quarter ended March 31, 2003.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

BIO-TECHNOLOGY GENERAL CORP.

 

 

 

 

(Registrant)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

By:

/s/ Whitney K. Stearns, Jr.

 

 

 

 

 

 

Whitney K. Stearns, Jr.

 

 

 

 

 

Senior Vice President—Chief Financial Officer and Treasurer

 

 

Dated: May 1, 2003

 

3